|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we demonstrate that neuroblastoma cells overcome the interference of tumor suppressor p16<sup>INK4a</sup> in cell proliferation, which is due to its latent interaction with CDK4 and CDK6.
|
31692039 |
2020 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of CDK4 was positively associated with plasma PTH level (r = 0.60, p = 0.04) and tumor weight (r = 0.80, p = 0.02) of the adenoma patients, respectively.
|
31535356 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These data indicate that the combination of cytotoxic and cytostatic agents could represent an important modality in those tumor types that are relatively resistant to CDK4/6 inhibitors.
|
31745297 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor biopsy with genomic sequencing and repeat biomarker analysis in patients with CDK4/6i- and endocrine-resistant disease will be integral to guide subsequent treatment strategies and to inform clinical trial eligibility.
|
31780379 |
2020 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
CDKN2A and CDK4 are well-established melanoma susceptibility genes, but their effect on tumor location and distribution is unknown.
|
31326397 |
2020 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
NF1 loss promoted ER-independent cyclin D1 expression, which could be therapeutically targeted with CDK4/6 inhibitors <i>in vitro</i> Patients with <i>NF1</i> mutations detected in baseline circulating tumour DNA had a good outcome on the CDK4/6 inhibitor palbociclib and fulvestrant.
|
31591187 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Compared with the well-known CDK4/6 inhibitor palbociclib, orally administered SHR6390 led to equivalent or improved tumor efficacy against a panel of carcinoma xenografts, and produced marked tumor regression in some models, in association with sustained target inhibition in tumor tissues.
|
30724426 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CDK4/6 inhibitors significantly suppress the PDX tumor growth with abnormal CDK4 pathway.
|
31358010 |
2019 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
On the one hand, CDK4 phosphorylated the tumor suppressor folliculin (FLCN), regulating mTORC1 recruitment to the lysosomal surface in response to amino acids.
|
31395606 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Besides the identification of well-recognized driver mutations of <i>BRAF</i> (3.1%), <i>RAS</i> family (6.2%), <i>NF1</i> (7.8%), and <i>KIT</i> (23.1%) in MMs, our study also found that (i) mutations and amplifications in the transmembrane nucleoporin gene <i>POM121</i> (30.8%) defined a patient subgroup with higher tumor proliferation rates; (ii) enrichment of structural variations between chromosomes 5 and 12 defined a patient subgroup with significantly worse clinical outcomes; (iii) over 50% of the MM patients harbored recurrent focal amplification of several oncogenes (<i>CDK4, MDM2,</i> and <i>AGAP2</i>) at 12q13-15, and this co-occurred significantly with amplification of <i>TERT</i> at 5p15, which was verified in the validation cohort; (iv) the PDX trial demonstrated robust antitumor effects of palbociclib in MMs harboring <i>CDK4</i> amplification.
|
30782616 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Concurrent targeting of BMI1 and CDK4/6 abrogates tumor growth in vitro and in vivo.
|
31548560 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CDK4/6 inhibition may prevent tumor cell progression in the cell cycle.
|
31369120 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The CDK4/6 inhibitor palbociclib reduces tumor growth by decreasing retinoblastoma (RB) protein phosphorylation and inducing cell cycle arrest at the G1/S phase transition.
|
30700828 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, coadministration of CDK4/6 and MDM2 antagonists with standard of care therapy caused tumor regression.
|
31413145 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor response rates with CDK4/6 inhibitor plus AI therapy are comparable to those with first-line cytotoxic chemotherapy.
|
30655702 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Preclinical studies from multiple tumor types suggest that other factors also affect the sensitivity of individual tumors to Cdk4/6 inhibitor.
|
30772267 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SCCOHT patient tumors are deficient in cyclin D1 yet retain the retinoblastoma-proficient/p16<sup>INK4a</sup>-deficient profile associated with positive responses to CDK4/6 inhibitors.
|
30718512 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In C33A xenografts, Ribociclib inhibited tumor growth associated with decreased expressions of CDK4, CDK6, cyclin D1, Rb and Ki-67, and also significantly increased tumor cell apoptosis.
|
30784916 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are an established treatment in estrogen receptor-positive breast cancer and are currently in clinical development in melanoma, a tumor that exhibits high rates of CDK4 activation.
|
31439820 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Novel therapeutic strategy with combination of a selective CDK4/6 inhibitor palbociclib (PAL) with a tyrosine kinase inhibitor (TKI) sorafenib (SOR) is reported to impair tumour growth and significantly increased survival in various preclinical models of HCC.
|
30660839 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Consistent with circadian regulation, a CDK4/6 inhibitor approved for cancer treatment reduced growth of cultured cells and mouse tumors in a time-of-day-specific manner.
|
31039152 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The micro-SPECT/CT study showed that complex <sup>99m</sup>Tc-<b>L4</b> had visible uptake at the tumor site, and the accumulation was clearly reduced in the image after pretreatment with palbociclib, further indicating CDK4/6 specificity.
|
31424939 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CDK4/6 inhibitors are a promising treatment strategy in tumor therapy but are hampered by resistance mechanisms.
|
31331377 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Modulation of pharmacodynamic markers of ribociclib CDK 4/6 inhibition in tumor tissues were inconsistent between study participants.
|
31399936 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Of additional importance, this combined treatment has potent efficacy in ESCC cells with acquired resistance to CDK4/6 inhibitors in vitro and in xenograft tumors.
|
30899002 |
2019 |